FDA: July 23-24, 2026 Pharmacy Compounding Advisory Committee Meeting Provides the official agenda, substances and uses evaluated, meeting materials, and archived broadcasts
FDA Regulatory Status The FDAs position is unambiguous: BPC-157 is not an approved drug for any medical condition
Stable Gastric Pentadecapeptide BPC 157 in Trials for Inflammatory Bowel Disease (PL-10, PLD-116, PL 14736, Pliva) Current Pharmaceutical Design Comprehensive review of BPC 157 clinical development for inflammatory bowel disease including ulcerative colitis trials, demonstrating mucosal healing and anti-inflammatory effects across multiple organ systems
The peptide is believed to stimulate the production of telomerase, an enzyme responsible for maintaining the length of telomeres protective caps at the ends of chromosomes
If you're taking oral copper or zinc supplements, space them at least 2 hours from each other
Christoph GR, Leonzio RJ, Wilcox KS